These enzyme-linked immunosorbent assays can detect two different forms of beta amyoid and synuclein - proteins found in Alzheimer's and Parkinson's diseases
Amersham Biosciences now offers an extensive range of fully validated Biotrak assay kits for markers of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.
These enzyme-linked immunosorbent assays (Elisas), which can detect two different forms of beta amyoid and synuclein, are validated for a variety of sample types, including brain tissue, serum, plasma, and cerebrospinal fluid.
Each of the new Biotrak Elisas - beta amyloid 1-40, beta amyloid 1-42, and alpha synuclein - captures and detects a specific protein in biological samples.
These proteins are key biomarkers for neurodegenerative disease.
"With the launch of these new Biotrak assays, Amersham Biosciences offers an extensive range of sample validated Elisas for neurodegenerative disease research," says Cathy Howat, vice president marketing, cell analysis and screening at Amersham Biosciences.
"Each assay is fully configured and validated to save customers time and resources. "Convenient protocols allow researchers to incubate the assays overnight".
Amersham Biosciences has developed validated, antibody-based assays for beta amyloid 1-40, beta amyloid 1-42, and synuclein, which are proteins that tend to accumulate to abnormal levels in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
These proteins may play an early and perhaps contributing role in several common neurodegenerative disorders.
The ability to detect and measure these proteins in patient samples using the Biotrak system may accelerate neurodegenerative disease research and help scientists better understand these complex disorders.
